Abstract
Concurrent chemotherapy and radiotherapy confers a significant, but small, benefit for overall survival compared with sequential chemoradiotherapy. The improvement of about 4% with a hazard ratio of 0.85 has only been proven for fit patients with a good organ function. From non-randomised trials, there are no indications that concurrent chemoradiotherapy is clearly superior to the sequential approach in other patients. Moreover, radiotherapy alone can lead to 5 year survival rates of 20%. As the differences in long-term survival between the treatment options are small, even fit patients should be offered, via a shared decision process, the choice between concurrent and non-concurrent chemotherapy and radiotherapy. In less fit patients, sequential chemoradiotherapy offers a chance for long-term survival and cure with less toxicity than the concurrent approach.
Original language | English |
---|---|
Pages (from-to) | 708-711 |
Journal | Clinical Oncology |
Volume | 28 |
Issue number | 11 |
DOIs | |
Publication status | Published - Nov 2016 |
Keywords
- Combined modality treatment
- concurrent
- elderly
- frail
- non-small cell lung cancer
- sequential